Navigation Links
China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Date:9/2/2008

HARBIN, China, Sept. 2 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (AMEX: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has received approval to list its common stock on the NASDAQ Global Market.

China Sky One expects to start trading on the NASDAQ Global Market on September 15, 2008, and that the last day of trading on the American Stock Exchange ("AMEX") will be September 12, 2008. The trading symbol for China Sky One's common stock on the NASDAQ Global Market will be "CSKI". The Company primarily sells its products in the People's Republic of China (PRC).

"We are very excited to list on NASDAQ and consider the change to be a significant milestone in China Sky One's development as a U.S. public company," commented Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One. "We are confident that the listing on NASDAQ will allow us to further enlarge our investor base and increase both our liquidity and visibility in the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

Mr. Yu-Bo Hao, Board Secretary

China Sky One Medical, Inc.

Tel: +86-0451-53994069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Investor Relations

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web site: http://www.ccgir.com

Mr. Richard Micchelli, Financial Writer

CCG Investor Relations

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web site: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
2. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. China Kangtai Cactus Biotech Announces Record Second Quarter Results
6. China Biologic Products Reports Second Quarter 2008 Results
7. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
8. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
9. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
10. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
11. China Medicine Announces Strong Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):